Symbols / UNCY Stock $8.08 +1.25% Unicycive Therapeutics, Inc.

Healthcare • Biotechnology • United States • NCM
UNCY (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO —
Exch · Country NCM · United States
Market Cap 215.74M
Enterprise Value 160.25M
Income -26.55M
Sales —
FCF (ttm) -22.92M
Book/sh 1.36
Cash/sh 1.64
Employees 21
Insider 10d —
IPO Jul 12, 2021
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E 1.18
PEG —
P/S —
P/B 5.92
P/C —
EV/EBITDA -5.43
EV/Sales —
Quick Ratio 2.18
Current Ratio 2.58
Debt/Eq 0.39
LT Debt/Eq —
EPS (ttm) -1.67
EPS next Y 6.84
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-03-30
Earnings (prior) 2026-03-30
ROA -45.66%
ROE -141.15%
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 26.70M
Shs Float 22.82M
Insider Own 2.36%
Instit Own 32.22%
Short Float 8.80%
Short Ratio 4.07
Short Interest 2.16M
52W High 11.00
vs 52W High -26.55%
52W Low 3.71
vs 52W Low 117.79%
Beta 1.77
Impl. Vol. 48.02%
Rel Volume 1.91
Avg Volume 504.26K
Volume 962.51K
Target (mean) $41.31
Tgt Median $34.50
Tgt Low $15.00
Tgt High $90.00
# Analysts 10
Recom Strong_buy
Prev Close $7.98
Price $8.08
Change 1.25%
About

Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases in the United States. It develops oxylanthanum carbonate, a lanthanum-based phosphate binding agent, which is for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI-494, a nicotinamide ester derivative and a selective ATP-sensitive mitochondrial potassium channel activator, which is in Phase I clinical trial for the treatment of acute kidney injury and pre-clinical stage for the treatment of chronic kidney disease. The company was incorporated in 2016 and is headquartered in Mountain View, California.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$41.31
Mean price target
2. Current target
$8.08
Latest analyst target
3. DCF / Fair value
$-15.45
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$8.08
Low
$15.00
High
$90.00
Mean
$41.31

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-04-06 main Benchmark Speculative Buy → Speculative Buy $15
2026-04-02 main Guggenheim Buy → Buy $40
2025-10-29 main HC Wainwright & Co. Buy → Buy $22
2025-09-15 main Benchmark Speculative Buy → Speculative Buy $21
2025-04-21 init Guggenheim — → Buy $6
2025-04-11 reit HC Wainwright & Co. Buy → Buy $8
2025-04-01 main HC Wainwright & Co. Buy → Buy $8
2025-01-29 reit HC Wainwright & Co. Buy → Buy $4
2025-01-08 main HC Wainwright & Co. Buy → Buy $4
2024-11-22 reit Benchmark Speculative Buy → Speculative Buy $3
2024-11-14 main HC Wainwright & Co. Buy → Buy $4
2024-11-12 reit HC Wainwright & Co. Buy → Buy $3
2024-10-09 reit HC Wainwright & Co. Buy → Buy $3
2024-09-06 reit Benchmark Speculative Buy → Speculative Buy $3
2024-09-03 reit HC Wainwright & Co. Buy → Buy $3
2024-08-15 main HC Wainwright & Co. Buy → Buy $3
2024-07-10 reit HC Wainwright & Co. Buy → Buy $5
2024-06-25 reit HC Wainwright & Co. Buy → Buy $5
2024-06-03 reit Benchmark Speculative Buy → Speculative Buy $3
2024-05-31 reit Benchmark Speculative Buy → Speculative Buy $3
News
RSS: Latest UNCY news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2025-08-25 AGGARWAL GAURAV Director — 652,900 — —
2025-02-18 AGGARWAL GAURAV Director — 1,400,000 — —
2024-10-09 AGGARWAL GAURAV Director — 5,500,000 — —
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
0.00
-100.00%
0.68
-29.02%
0.95
Operating Revenue
0.00
0.00
-100.00%
0.68
-29.02%
0.95
Operating Expense
29.52
-8.10%
32.12
+49.74%
21.45
+12.87%
19.00
Research And Development
9.12
-54.43%
20.01
+55.12%
12.90
+3.75%
12.44
Selling General And Administration
20.40
+68.52%
12.10
+41.61%
8.55
+30.15%
6.57
General And Administrative Expense
20.40
+68.52%
12.10
+41.61%
8.55
+30.15%
6.57
Other Gand A
20.40
+68.52%
12.10
+41.61%
8.55
+30.15%
6.57
Total Expenses
29.52
-8.10%
32.12
+49.74%
21.45
+12.87%
19.00
Operating Income
-29.52
+8.10%
-32.12
-54.60%
-20.77
-15.08%
-18.05
Total Operating Income As Reported
-29.52
+8.10%
-32.12
-54.60%
-20.77
-15.08%
-18.05
EBITDA
-25.91
+28.48%
-36.23
-20.05%
-30.18
-68.68%
-17.89
Normalized EBITDA
-27.93
+8.20%
-30.43
-53.10%
-19.88
-11.09%
-17.89
Reconciled Depreciation
0.57
+33.64%
0.43
+50.70%
0.28
+76.40%
0.16
EBIT
-26.48
+27.75%
-36.66
-20.34%
-30.46
-68.75%
-18.05
Total Unusual Items
2.02
+134.83%
-5.80
+43.69%
-10.30
0.00
Total Unusual Items Excluding Goodwill
2.02
+134.83%
-5.80
+43.69%
-10.30
0.00
Special Income Charges
—
—
—
0.00
Other Special Charges
—
—
—
—
Net Income
-26.55
+27.70%
-36.73
-20.25%
-30.54
-69.14%
-18.06
Pretax Income
-26.55
+27.70%
-36.73
-20.25%
-30.54
-69.14%
-18.06
Net Non Operating Interest Income Expense
0.94
-20.92%
1.19
+123.26%
0.53
+8983.33%
-0.01
Interest Expense Non Operating
0.07
+0.00%
0.07
-13.41%
0.08
+1266.67%
0.01
Net Interest Income
0.94
-20.92%
1.19
+123.26%
0.53
+8983.33%
-0.01
Interest Expense
0.07
+0.00%
0.07
-13.41%
0.08
+1266.67%
0.01
Interest Income Non Operating
1.01
-19.75%
1.26
+105.04%
0.61
0.00
Interest Income
1.01
-19.75%
1.26
+105.04%
0.61
0.00
Other Income Expense
2.02
+134.83%
-5.80
+43.69%
-10.30
—
Gain On Sale Of Security
2.02
+134.83%
-5.80
+43.69%
-10.30
—
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-26.55
+27.70%
-36.73
-20.25%
-30.54
-69.14%
-18.06
Net Income From Continuing Operation Net Minority Interest
-26.55
+27.70%
-36.73
-20.25%
-30.54
-69.14%
-18.06
Net Income From Continuing And Discontinued Operation
-26.55
+27.70%
-36.73
-20.25%
-30.54
-69.14%
-18.06
Net Income Continuous Operations
-26.55
+27.70%
-36.73
-20.25%
-30.54
-69.14%
-18.06
Normalized Income
-28.58
+7.60%
-30.93
-52.79%
-20.24
-12.09%
-18.06
Net Income Common Stockholders
-26.55
+29.79%
-37.82
-20.42%
-31.41
-73.95%
-18.06
Diluted EPS
—
-5.65
+55.86%
-12.80
-6.67%
-12.00
Basic EPS
—
-5.65
+55.86%
-12.80
-6.67%
-12.00
Basic Average Shares
—
6.70
+172.97%
2.45
+62.98%
1.51
Diluted Average Shares
—
6.70
+172.97%
2.45
+62.98%
1.51
Diluted NI Availto Com Stockholders
-26.55
+29.79%
-37.82
-20.42%
-31.41
-73.95%
-18.06
Preferred Stock Dividends
—
1.09
+26.30%
0.87
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
49.13
+55.16%
31.67
+123.16%
14.19
+403.58%
2.82
Current Assets
48.96
+58.20%
30.95
+130.97%
13.40
+406.77%
2.64
Cash Cash Equivalents And Short Term Investments
41.27
+57.86%
26.14
+169.48%
9.70
+2032.09%
0.46
Cash And Cash Equivalents
29.20
+11.69%
26.14
+169.48%
9.70
+2032.09%
0.46
Cash Financial
29.20
+11.69%
26.14
+169.48%
9.70
+2032.09%
0.46
Other Short Term Investments
12.07
0.00
—
—
Prepaid Assets
6.52
+68.63%
3.87
+14.65%
3.37
+66.16%
2.03
Current Deferred Assets
—
—
—
—
Other Current Assets
1.17
+24.71%
0.94
+188.92%
0.33
+104.40%
0.16
Total Non Current Assets
0.17
-75.83%
0.72
-9.09%
0.79
+355.17%
0.17
Net PPE
0.17
-75.83%
0.72
-9.09%
0.79
+355.17%
0.17
Gross PPE
0.25
-67.59%
0.76
-6.06%
0.81
+346.41%
0.18
Accumulated Depreciation
-0.07
-84.62%
-0.04
-143.75%
-0.02
-128.57%
-0.01
Properties
0.00
0.00
0.00
0.00
Buildings And Improvements
0.11
-83.26%
0.65
-15.80%
0.77
+403.95%
0.15
Machinery Furniture Equipment
0.05
+20.51%
0.04
+85.71%
0.02
+50.00%
0.01
Construction In Progress
—
0.01
0.00
—
Other Properties
0.03
+0.00%
0.03
—
—
Leases
0.07
+32.65%
0.05
+133.33%
0.02
+40.00%
0.01
Total Liabilities Net Minority Interest
18.94
-21.86%
24.24
+34.65%
18.00
+448.11%
3.28
Current Liabilities
18.94
-21.48%
24.12
+37.56%
17.53
+433.92%
3.28
Payables And Accrued Expenses
1.82
-59.72%
4.53
+11.66%
4.05
+31.53%
3.08
Payables
0.30
-68.84%
0.97
+17.66%
0.82
-2.96%
0.85
Accounts Payable
0.30
-68.84%
0.97
+17.66%
0.82
-2.96%
0.85
Current Accrued Expenses
1.52
-57.24%
3.56
+10.14%
3.23
+44.57%
2.24
Current Debt And Capital Lease Obligation
0.20
-69.66%
0.66
+90.14%
0.34
+71.64%
0.20
Current Debt
0.08
-10.87%
0.09
+411.11%
0.02
-60.87%
0.05
Current Capital Lease Obligation
0.12
-79.26%
0.56
+72.48%
0.33
+110.97%
0.15
Other Current Liabilities
16.91
-10.67%
18.94
+44.18%
13.13
—
Total Non Current Liabilities Net Minority Interest
0.00
-100.00%
0.12
-74.89%
0.47
0.00
Long Term Debt And Capital Lease Obligation
0.00
-100.00%
0.12
-74.89%
0.47
0.00
Long Term Capital Lease Obligation
0.00
-100.00%
0.12
-74.89%
0.47
0.00
Stockholders Equity
30.20
+306.37%
7.43
+295.09%
-3.81
-717.38%
-0.47
Common Stock Equity
30.20
+306.37%
7.43
+295.09%
-3.81
-717.38%
-0.47
Capital Stock
0.02
+100.00%
0.01
-68.57%
0.04
+133.33%
0.01
Common Stock
0.02
+100.00%
0.01
-68.57%
0.04
+133.33%
0.01
Preferred Stock
0.00
0.00
0.00
0.00
Share Issued
22.11
+94.25%
11.38
+227.55%
3.48
+128.18%
1.52
Ordinary Shares Number
22.11
+94.25%
11.38
+227.55%
3.48
+128.18%
1.52
Additional Paid In Capital
158.00
+45.37%
108.69
+79.07%
60.70
+81.10%
33.52
Retained Earnings
-127.83
-26.22%
-101.27
-56.91%
-64.54
-89.84%
-34.00
Gains Losses Not Affecting Retained Earnings
-0.00
0.00
—
—
Other Equity Adjustments
-0.00
—
—
—
Total Equity Gross Minority Interest
30.20
+306.37%
7.43
+295.09%
-3.81
-717.38%
-0.47
Total Capitalization
30.20
+306.37%
7.43
+295.09%
-3.81
-717.38%
-0.47
Working Capital
30.02
+339.70%
6.83
+265.13%
-4.13
-546.09%
-0.64
Invested Capital
30.28
+302.49%
7.52
+298.44%
-3.79
-802.62%
-0.42
Total Debt
0.20
-74.26%
0.77
-4.69%
0.81
+303.48%
0.20
Capital Lease Obligations
0.12
-82.82%
0.68
-14.12%
0.79
+411.61%
0.15
Net Tangible Assets
30.20
+306.37%
7.43
+295.09%
-3.81
-717.38%
-0.47
Tangible Book Value
30.20
+306.37%
7.43
+295.09%
-3.81
-717.38%
-0.47
Dueto Related Parties Current
—
—
—
—
Line Of Credit
0.08
-10.87%
0.09
+411.11%
0.02
-60.87%
0.05
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-31.32
-9.60%
-28.57
-56.29%
-18.28
-16.82%
-15.65
Cash Flow From Continuing Operating Activities
-31.32
-9.59%
-28.58
-56.30%
-18.28
-16.82%
-15.65
Net Income From Continuing Operations
-26.55
+27.70%
-36.73
-20.25%
-30.54
-69.14%
-18.06
Depreciation Amortization Depletion
0.57
+33.64%
0.43
+50.70%
0.28
+76.40%
0.16
Depreciation
0.57
+33.64%
0.43
+50.70%
0.28
+76.40%
0.16
Depreciation And Amortization
0.57
+33.64%
0.43
+50.70%
0.28
+76.40%
0.16
Other Non Cash Items
—
0.00
—
0.02
Pension And Employee Benefit Expense
—
—
—
0.00
Stock Based Compensation
2.64
+12.38%
2.35
+32.99%
1.77
+68.77%
1.05
Operating Gains Losses
-2.02
-134.83%
5.80
-43.69%
10.30
—
Gain Loss On Investment Securities
-2.02
-134.83%
5.80
-43.69%
10.30
—
Change In Working Capital
-5.95
-1294.38%
-0.43
-359.14%
-0.09
-107.89%
1.18
Change In Prepaid Assets
-2.88
-251.71%
-0.82
+26.59%
-1.12
-1901.61%
0.06
Change In Payables And Accrued Expense
-2.50
-417.09%
0.79
-38.09%
1.28
+0.71%
1.27
Change In Payable
-2.50
-417.09%
0.79
-38.09%
1.28
+0.71%
1.27
Change In Account Payable
-2.50
-417.09%
0.79
-38.09%
1.28
+0.71%
1.27
Change In Other Current Liabilities
-0.56
-42.32%
-0.40
-57.54%
-0.25
-66.89%
-0.15
Investing Cash Flow
-12.10
-16698.61%
-0.07
-500.00%
-0.01
-500.00%
-0.00
Cash Flow From Continuing Investing Activities
-12.10
-16698.61%
-0.07
-500.00%
-0.01
-500.00%
-0.00
Net PPE Purchase And Sale
-0.02
+66.67%
-0.07
-500.00%
-0.01
-500.00%
-0.00
Purchase Of PPE
-0.02
+66.67%
-0.07
-500.00%
-0.01
-500.00%
-0.00
Capital Expenditure
-0.02
+66.67%
-0.07
-500.00%
-0.01
-500.00%
-0.00
Net Investment Purchase And Sale
-12.07
0.00
—
—
Purchase Of Investment
-12.07
0.00
—
—
Financing Cash Flow
46.47
+3.06%
45.09
+63.71%
27.54
+5947.35%
-0.47
Cash Flow From Continuing Financing Activities
46.47
+3.06%
45.09
+63.71%
27.54
+5947.35%
-0.47
Net Issuance Payments Of Debt
—
—
—
0.00
Issuance Of Debt
—
—
—
0.00
Repayment Of Debt
—
—
—
0.00
Long Term Debt Issuance
—
—
—
0.00
Long Term Debt Payments
—
—
—
0.00
Net Long Term Debt Issuance
—
—
—
0.00
Net Common Stock Issuance
46.58
+6720.20%
0.68
0.00
-100.00%
0.01
Cash Dividends Paid
0.00
+100.00%
-1.09
0.00
—
Proceeds From Stock Option Exercised
1.50
0.00
—
0.00
Net Other Financing Charges
-1.61
+64.22%
-4.50
-69.88%
-2.65
-449.59%
-0.48
Changes In Cash
3.06
-81.41%
16.44
+77.82%
9.25
+157.34%
-16.12
Beginning Cash Position
26.14
+169.48%
9.70
+2032.09%
0.46
-97.26%
16.58
End Cash Position
29.20
+11.69%
26.14
+169.48%
9.70
+2032.09%
0.46
Free Cash Flow
-31.34
-9.40%
-28.65
-56.58%
-18.30
-16.88%
-15.65
Interest Paid Supplemental Data
0.00
-100.00%
0.01
-50.00%
0.02
+300.00%
0.01
Income Tax Paid Supplemental Data
—
0.00
0.00
0.00
Common Stock Issuance
46.58
+6720.20%
0.68
0.00
-100.00%
0.01
Issuance Of Capital Stock
46.58
-8.09%
50.68
+67.88%
30.19
+274354.55%
0.01
Net Preferred Stock Issuance
0.00
-100.00%
50.00
+65.62%
30.19
0.00
Preferred Stock Issuance
0.00
-100.00%
50.00
+65.62%
30.19
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category